RECORD // Company

Valion Bio, Inc.

Formerly: Tivic Health Systems, Inc.

Built 2026-11-21T20:43:15Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Tivic Health Systems · Ctgov · name equals 'Tivic Health Systems' but other unrelated entities share it Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-06-30, filed 2026-08-14 · accession 0001437749-26-028069

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-7,103,0003 months ended 2026-06-3010-Q2026-08-140001437749-26-0280692026-11-21 20:43 UTCReport an error
Interest expense$691,0003 months ended 2026-06-3010-Q2026-08-140001437749-26-0280692026-11-21 20:43 UTCReport an error
Cash and cash equivalents$2,108,000at 2026-06-3010-Q2026-08-140001437749-26-0280692026-11-21 20:43 UTCReport an error
Contract liabilities (total) (from an earlier report)$3,000at 2025-09-3010-Q2025-11-140001437749-25-0352162026-11-21 20:43 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001787740
Ticker
VBIO
EIN
814016391
CUSIP
918942202
Record ID
sx:sec:0001787740

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

28 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-21 20:43 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-21 20:43 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-21 20:43 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-21 20:43 UTCReport an error
Business address1305 E. HOUSTON STREET, BUILDING 1, SUITE 311, SAN ANTONIO, TX, 782052026-11-16SEC EDGAR company profile2026-11-21 20:43 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-21 20:43 UTCReport an error
Revenue (fiscal year ended 2024-12-31)$780,0002024-12-3110-K, XBRL Revenues2026-11-21 20:43 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-8,878,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-21 20:43 UTCReport an error
Total assets (at 2025-12-31)$31,607,0002025-12-3110-K, XBRL Assets2026-11-21 20:43 UTCReport an error
Stockholders' equity (at 2025-12-31)$16,797,0002025-12-3110-K, XBRL StockholdersEquity2026-11-21 20:43 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$12,645,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-21 20:43 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-6,999,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-21 20:43 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$38,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-21 20:43 UTCReport an error
Form D total offering amount (D filed 2025-12-29)$75,000,0002025-12-29D2026-11-21 20:43 UTCReport an error
Form D total amount sold (D filed 2025-12-29)$12,000,0002025-12-29D2026-11-21 20:43 UTCReport an error
Form D industry groupBiotechnology2025-12-29D2026-11-21 20:43 UTCReport an error
Form D revenue rangeDecline to Disclose2025-12-29D2026-11-21 20:43 UTCReport an error
Form D date of first sale2025-12-102025-12-29D2026-11-21 20:43 UTCReport an error
8-K Item 5.02, Departure of Directors or Certain (filed 2026-11-16)Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 12, 2026, the stockholders of Valion Bio, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”) to increase the number of shares of common stock authorized for issuance thereunder by 272,000 shares (the “Plan Amendment”). The Plan Amendment became effective upon stockholder approval. Except for the increase in the share reserve and related conforming changes, the Plan Amendment did not change any other term or provision of the 2021 Plan.2026-11-16SEC EDGAR 8-K 0001683168-26-008851 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote of (filed 2026-11-16)Security Holders. On November 12, 2026, the Company held a special meeting of stockholders in a virtual format (the “Special Meeting”). As of the close of business on October 15, 2026, the record date for the Special Meeting, there were 2,155,637 shares of the Company’s common stock issued and outstanding and entitled to vote. At the Special Meeting, 1,125,685 shares, or approximately 52.22% of the shares entitled to vote, were represented virtually or by proxy, constituting a quorum. Holders of the Company’s Series A, Series B and Series C Non-Voting Convertible Preferred Stock were not entitled to vote those shares on the matters presented at the Special Meeting. The proposals are more…2026-11-16SEC EDGAR 8-K 0001683168-26-008851 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-11-09)Series B Closing Valion Bio, Inc., a Delaware corporation (the “Company”), and 3i, LP (“3i”) are party to that certain Securities Purchase Agreement, dated as of April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the purchase and sale of (a) up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Shares”) and (b) warrants (“Series B Warrants”) to purchase a number of shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) at an initial exercise price per share determined pursuant to Section 2.2 of the Series B Preferred Purchase…2026-11-09SEC EDGAR 8-K 0001683168-26-008390 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-11-09)The information contained in Item 1.01 is hereby incorporated by reference into this Item 3.02.2026-11-09SEC EDGAR 8-K 0001683168-26-008390 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 5.02, Departure of Directors or Certain (filed 2026-11-05)Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.2026-11-05SEC EDGAR 8-K 0001683168-26-008352 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 5.02, (b) (filed 2026-11-05)On October 31, 2026, Lisa Wolf notified the Special Committee of the Board of Directors of Valion Bio, Inc. (the “Company”) of her decision to voluntarily resign from her positions as President, Chief Operating Officer and Chief Financial Officer of the Company. Ms. Wolf’s resignation from each of these positions will become effective on December 11, 2026. Accordingly, as of the date of this Current Report on Form 8-K, Ms. Wolf’s resignation has not yet become effective. 22026-11-05SEC EDGAR 8-K 0001683168-26-008352 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 5.02, Departure of Directors or Certain (filed 2026-11-02)Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.2026-11-02SEC EDGAR 8-K 0001683168-26-008221 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 5.02, (b) (filed 2026-11-02)On October 27, 2026, Valion Bio, Inc. (the “Company”) notified Melinda Lackey, the Company’s General Counsel and Senior Vice President of Legal Affairs, of the termination of her employment, effective October 30, 2026.2026-11-02SEC EDGAR 8-K 0001683168-26-008221 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 5.02, (e) (filed 2026-11-02)On October 31, 2026, the Company entered into a Separation Agreement and General Release (the “Separation Agreement”) with Melinda Lackey. Under the Separation Agreement, subject to Ms. Lackey’s compliance with its terms and the satisfaction of the conditions set forth therein, the Company agreed to pay Ms. Lackey a gross cash severance payment of $26,750, less applicable taxes and withholdings, in a single lump-sum payment no later than 30 days following the effective date of the Separation Agreement. In addition, if Ms. Lackey is eligible for and properly elects continued medical or dental coverage under COBRA, the Company agreed to pay the applicable COBRA premiums for Ms. Lackey and her…2026-11-02SEC EDGAR 8-K 0001683168-26-008221 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-11-02)On October 30, 2026, Valion Bio, Inc. (the “Company”) announced the evaluation of its lead biologic drug candidate, Entolimod, by the Armed Forces Radiobiology Research Institute in connection with research relating to gastrointestinal acute radiation syndrome in a therapeutic efficacy study. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.2026-11-02SEC EDGAR 8-K 0001683168-26-008221 (text as filed, excerpt)2026-11-21 20:43 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.